This decision overturned a $107.5 million infringement award. The CAFC held that Wyeth’s method of treatment claims were invalid for lack of enablement because the patent did not disclose to the skilled person how to identify a therapeutically effective daily...
Abbott is the proprietor of a patent describing a continuous glucose monitoring device and a method of assembling the same. SiBio provide devices for continuous ketone monitoring, and Abbott were concerned that they were about to launch a new product that would...
As a reminder, this case addresses how the Hatch-Waxman act “carve-out” provisions (which has led to the emergence of “skinny labels”) interacts with US law on induced patent infringement. This case is the first time the US Supreme Court has had the opportunity to...
On 16–17 June 2026, the Court heard Otsuka’s appeal in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd. The appeal challenges the Full Federal Court’s finding that formulation patents are not eligible for patent term extensions (PTEs). The decision, expected in...
Overview Broad antibody claims have faced a difficult path in the US since Amgen v Sanofi, particularly where the claim covers a large functional genus. The Federal Circuit’s decision in Teva v Eli Lilly is therefore interesting because the court drew an important...
Recent Comments